Incidence and development of cholestasis in surgical neonates receiving an intravenous mixed-oil lipid emulsion.

ABSTRACT:

Background

Intestinal failure-associated liver disease (IFALD), initially manifesting as cholestasis, is a complication in neonates receiving parenteral nutrition (PN). Soybean oil lipid emulsion (SOLE), though implicated in IFALD, was the only US Food and Drug Administration (FDA)-approved initial intravenous lipid emulsion (ILE) for infants and children in the United States. A mixed-oil lipid emulsion (MOLE) gained popularity in patients at risk for IFALD and was recently FDA approved as an initial ILE in children. Given the presence of soybean oil in MOLE, we hypothesized that MOLE would not be effective at preventing cholestasis in surgical neonates.

Methods

Neonates with gastrointestinal surgical conditions necessitating PN for ≥14 days and receiving MOLE (SMOFlipid) fr

SUBMITTER: Yu LJ 

PROVIDER: S-EPMC9839605 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature